Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 4, 2011, Pages 238-244

  Tan, Orkun ^a   Bukulmez, Orhan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cell biology; gonadotropin releasing hormone; gonadotropin releasing hormone antagonist; gonadotropin releasing hormone receptor

Indexed keywords

ABARELIX; CETRORELIX; DEGARELIX; ELAGOLIX; ESTRADIOL; F 75998; G PROTEIN COUPLED RECEPTOR; GANIRELIX; GONADORELIN; GONADORELIN ANTAGONIST; ITURELIX; LUTEINIZING HORMONE; OZARELIX; PROGESTERONE; SUFUGOLIX; TEVERELIX; UNCLASSIFIED DRUG; WAY 207024;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PALLIATIVE THERAPY; CELL PROLIFERATION; CYTOLOGY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FERTILIZATION IN VITRO; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE RELEASE; MOLECULAR BIOLOGY; NIDATION; NONHUMAN; OVARY CANCER; OVARY HYPERSTIMULATION; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UTERUS MYOMA;

BREAST NEOPLASMS; EMBRYO IMPLANTATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; OVULATION INDUCTION; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION;

EID: 79960836271     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328348a3ce     Document Type: Review

References (92)

1. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994; 45:391-405. (Pubitemid 24158170)
2. Ata B, Urman B. Single dose Gn RH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of Gn RH analogue used for pituitary suppression? Reprod Biomed Online 2010; 20:165-166; author reply 167.
3. Kiesel LA, Rody A, Greb RR, Szilagyi A. Clinical use of Gn RH analogues. Clin Endocrinol (Oxf) 2002; 56:677-687.
4. Shalev E, Leung PC. Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can 2003; 25:98-113.
5. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998; 95:305-309. (Pubitemid 28103949)
6. Yahalom D, Chen A, Ben-Aroya N, et al. The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. FEBS Lett 1999; 463:289-294. (Pubitemid 30001937)
7. Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (Gn RH)-I, Gn RH-II, and their receptors in humans. Endocr Rev 2005; 26:283-306.
8. Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev 2004; 25:235-275. (Pubitemid 38501395)
9. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog Horm Res 1995; 50:161-205.
10. Raga F, Casan EM, Kruessel JS, et al. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998; 59:661-669. (Pubitemid 28395084)
11. Casan EM, Raga F, Bonilla-Musoles F, Polan ML. Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. J Clin Endocrinol Metab 2000; 85:1377-1381. (Pubitemid 32289476)
12. Peterson CM, Jolles CJ, Carrell DT, et al. Gn RH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 1994; 52:26-30. (Pubitemid 24066848)
13. Kim KY, Choi KC, Auersperg N, Leung PC. Mechanism of gonadotropin- releasing hormone (Gn RH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the Gn RH-I receptor and protein kinase C pathway. Endocr Relat Cancer 2006; 13:211-220.
14. Khodr GS, Siler-Khodr TM. Placental luteinizing hormone-releasing factor and its synthesis. Science 1980; 207:315-317. (Pubitemid 10151629)
15. Siler-Khodr TM, Khodr GS. Extrahypothalamic luteinizing hormone-releasing factor (LRF): release of immunoreactive LRF in vitro. Fertil Steril 1979; 32:294-296. (Pubitemid 9245209)
16. Jelodar GA, Gholami S, Jafarpour F. Effect of Gn RH on guinea pig endometrium at preimplantation stage. Indian J Exp Biol 2007; 45:242-246.
17. Casan EM, Raga F, Polan ML. Gn RH m RNAand protein expression in human preimplantation embryos. Mol Hum Reprod 1999; 5:234-239. (Pubitemid 29104936)
18. Poon SL, Klausen C, Hammond GL, Leung PC. 37-k Da laminin receptor precursor mediates Gn RH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells. Mol Endocrinol 2011; 25:327-338.
19. Serin IS, Tanriverdi F, Ata CD, et al. Gn RH-II m RNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2010; 149:92-96.
20. Cheon KW, Lee HS, Parhar IS, Kang IS. Expression of the second isoform of gonadotrophin-releasing hormone (Gn RH-II) in human endometrium throughout the menstrual cycle. Mol Hum Reprod 2001; 7:447-452. (Pubitemid 32447770)
21. Choi KC, Auersperg N, Leung PC. Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2001; 86:5075-5078. (Pubitemid 33020567)
22. Kang SK, Tai CJ, Nathwani PS, Leung PC. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells. Endocrinology 2001; 142:182-192. (Pubitemid 32183680)
23. Schubert A, Hawighorst T, Emons G, Grundker C. Agonists and antagonists of Gn RH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Breast Cancer Res Treat 2011 [Epub ahead of print], 21279682 [PMID].
24. Chen A, Kaganovsky E, Rahimipour S, et al. Two forms of gonadotropin-releasing hormone (Gn RH) are expressed in human breast tissue and over-expressed in breast cancer: a putative mechanism for the antiproliferative effect of Gn RH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Res 2002; 62:1036-1044. (Pubitemid 34160284)
25. Harris N, Dutlow C, Eidne K, et al. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res 1991; 51:2577-2581.
26. Cui J, Smith RG, Mount GR, et al. Identification of Phe313 of the gonadotropin-releasing hormone (Gn RH) receptor as a site critical for the binding of nonpeptide Gn RH antagonists. Mol Endocrinol 2000; 14:671-681. (Pubitemid 32260511)
27. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997; 18:180-205. (Pubitemid 27171519)
28. Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994; 15:462-499. (Pubitemid 24271240)
29. Grosse R, Schmid A, Schoneberg T, et al. Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 2000; 275:9193-9200. (Pubitemid 30185136)
30. Harris D, Reiss N, Naor Z. Differential activation of protein kinase C delta and epsilon gene expression by gonadotropin-releasing hormone in alpha T3-1 cells. Autoregulation by protein kinase C. J Biol Chem 1997; 272:13534-13540. (Pubitemid 27224782)
31. Bramley TA, Stirling D, Swanston IA, et al. Specific binding sites for gonadotrophin-releasing hormone, LH/chorionic gonadotrophin, low-density lipoprotein, prolactin and FSH in homogenates of human corpus luteum. II: concentrations throughout the luteal phase of the menstrual cycle and early pregnancy. J Endocrinol 1987; 113:317-327. (Pubitemid 17071615)
32. Emons G, Pahwa GS, Brack C, et al. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25:215-221. (Pubitemid 19054823)
33. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993; 53:5439-5446. (Pubitemid 23342164)
34. Brus L, Lambalk CB, de Koning J, et al. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human preovulatory follicles. Hum Reprod 1997; 12:769-773. (Pubitemid 27223045)
35. Kobayashi Y, Zhai YL, Iinuma M, et al. Effects of a Gn RH analogue on human smooth muscle cells cultured from normal myometrial and from uterine leiomyomal tissues. Mol Hum Reprod 1997; 3:91-99. (Pubitemid 127509438)
36. Millar R, Lowe S, Conklin D, et al. A novel mammalian receptor for the evolutionary conserved type II Gn RH. Proc Natl Acad Sci USA 2001; 98:9636-9641. (Pubitemid 32769355)
37. Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (Gn RH) receptor specific for Gn RH II in primates. Biochem Biophys Res Commun 2001; 282:101 2-1018.
38. Kim KY, Choi KC, Park SH, et al. Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2004; 89:3020-3026.
39. Kim KY, Choi KC, Park SH, et al. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 2005; 90:1670-1677.
40. Morgan K, Conklin D, Pawson AJ, et al. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 2003; 144:423-436. (Pubitemid 36205212)
41. Faurholm B, Cochrane S, Millar RR, Katz AA. Gene structure and promoter functional analysis of the marmoset type II Gn RH receptor. J Mol Endocrinol 2007; 39:91-104. (Pubitemid 47337869)
42. Choi JH, Gilks CB, Auersperg N, Leung PC. Immunolocalization of gonadotropin-releasing hormone (Gn RH)-I, Gn RH-II, and type I Gn RH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 2006; 91:4562-4570. (Pubitemid 44833439)
43. Coetsee M, Millar RP, Flanagan CA, Lu ZL. Identification of Tyr(290(6.58)) of the human gonadotropin-releasing hormone (Gn RH) receptor as a contact residue for both Gn RH I and Gn RH II: importance for high-affinity binding and receptor activation. Biochemistry 2008; 47:10305-10313.
44. Olivennes F. The use of gonadotropin-releasing hormone antagonist in ovarian stimulation. Clin Obstet Gynecol 2006; 49:12-22. (Pubitemid 44375666)
45. Klingmuller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent Gn RH antagonist Cetrorelix. Acta Endocrinol (Copenh) 1993; 128:15-18. (Pubitemid 23055235)
46. Blockeel C, Sterrenburg MD, Broekmans FJ, et al. Follicular phase endocrine characteristics during ovarian stimulation and Gn RH antagonist cotreatment for IVF: Rct comparing rec FSH initiated on cycle day 2 or 5. J Clin Endocrinol Metab 2011; 96:1122-1128.
47. Griesinger G, Felberbaum R, Diedrich K. Gn RH-antagonists in reproductive medicine. Arch Gynecol Obstet 2005; 273:71-78.
48. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009; 94:545-551.
49. Hara T, Araki H, Kusaka M, et al. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J Clin Endocrinol Metab 2003; 88:1697-1704. (Pubitemid 36623391)
50. Wang C, Yun O, Maiti K, et al. Position of Pro and Ser near Glu7.32 in the extracellular loop 3 of mammalian and nonmammalian gonadotropin-releasing hormone (Gn RH) receptors is a critical determinant for differential ligand selectivity for mammalian Gn RH and chicken Gn RH-II. Mol Endocrinol 2004; 18:105-116. (Pubitemid 38073158)
51. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20:1247-1262. (Pubitemid 29512447)
52. Festuccia C, Dondi D, Piccolella M, et al. Ozarelix, a fourth generation Gn RH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate 2010; 70:1340-1349.
53. Berardelli R, Gianotti L, Karamouzis I, et al. Effects of cetrorelix, a Gn RH- receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea. Gynecol Endocrinol 2011 [Epub ahead of print]. 21204607 [PMID].
54. Duijkers IJ, Klipping C, Willemsen WN, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod 1998; 13:2392-2398. (Pubitemid 28451211)
55. Lin YH, Wen YR, Chang Y, et al. Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study. Fertil Steril 2010; 94:179-183.
56. Erb K, Klipping C, Duijkers I, et al. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 2001; 75:316-323. (Pubitemid 32112108)
57. Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 1995; 63:963-969.
58. Oberye JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 1999; 72:1001-1005.
59. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358:1793-1803. (Pubitemid 33153010)
60. Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of anew, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002; 301:95-102. (Pubitemid 34250284)
61. Taylor JE, Miller BT, Gray KD, et al. The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin- releasing hormone (Gn RH) agonist and primed with Gn RH antagonist. Fertil Steril 2010; 93:1668-1675.
62. Tarlatzis BC, Fauser BC, Kolibianakis EM, et al. Gn RH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006; 12:333-340.
63. Maudsley S, Davidson L, Pawson AJ, et al. Gonadotropin-releasing hormone (Gn RH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I Gn RH receptor. Cancer Res 2004; 64:7533-7544. (Pubitemid 39372098)
64. Enomoto M, Endo D, Kawashima S, Park MK. Human type II Gn RH receptor mediates effects of Gn RH on cell proliferation. Zoolog Sci 2004; 21:763-770. (Pubitemid 39151592)
65. Grundker C, Schlotawa L, Viereck V, et al. Antiproliferative effects of the Gn RH antagonist cetrorelix and of Gn RH-II on human endometrial and ovarian cancer cells are not mediated through the Gn RH type I receptor. Eur J Endocrinol 2004; 151:141-149. (Pubitemid 39117377)
66. Hsueh AJ, Jones PB. Extrapituitary actions of gonadotropin-releasing hormone. Endocr Rev 1981; 2:437-461.
67. Fekete M, Bajusz S, Groot K, et al. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 1989; 124:946-955. (Pubitemid 19057091)
68. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995; 80:430-434.
69. Murdoch WJ. Immunolocalization of a gonadotropin-releasing hormone receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 1995; 282:527-529.
70. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15:526-531. (Pubitemid 30142356)
71. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000; 15:1490-1498.
72. Fluker M, Grifo J, Leader A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75:38-45. (Pubitemid 32041225)
73. Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better? Fertil Steril 2001; 76:443-444. (Pubitemid 32776531)
74. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14:640-649.
75. Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2011; 95:164-169.
76. Giampietro F, Sancilio S, Tiboni GM, et al. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin- releasing hormone agonist or antagonist. Fertil Steril 2006; 85:412-419. (Pubitemid 43170916)
77. Garcia-Velasco JA, Isaza V, Vidal C, et al. Human ovarian steroid secretion in vivo: effects of Gn RH agonist versus antagonist (cetrorelix). Hum Reprod 2001; 16:2533-2539. (Pubitemid 34007467)
78. Winkler N, Bukulmez O, Hardy DB, Carr BR. Gonadotropin releasing hormone antagonists suppress aromatase and anti-Mullerian hormone expression in human granulosa cells. Fertil Steril 2010; 94:1832-1839.
79. Raga F, Casan EM, Kruessel J, et al. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 1999; 140:3705-3712. (Pubitemid 30645426)
80. Bukulmez O, Rehman KS, Langley M, et al. Precycle administration of Gn RH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation. Reprod Biomed Online 2006; 13:465-475. (Pubitemid 44548780)
81. Bukulmez O, Carr BR, Doody KM, Doody KJ. Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction. Fertil Steril 2008; 89:74-83.
82. Klemmt PA, Liu F, Carver JG, et al. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum Reprod 2009; 24:2187-2192.
83. Tug N, Uslu U, Cumbul A, et al. Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy. Eur J Obstet Gynecol Reprod Biol 2011; 155:166-170.
84. Olivennes F, Mannaerts B, Struijs M, et al. Perinatal outcome of pregnancy after Gn RH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod 2001; 16:1588-1591. (Pubitemid 32761735)
85. Boerrigter PJ, de Bie JJ, Mannaerts BM, et al. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the Gn RH antagonist ganirelix. Hum Reprod 2002; 17:2027-2034.
86. Elizur SE, Tulandi T. Drugs in infertility and fetal safety. Fertil Steril 2008; 89:1595-1602. (Pubitemid 351749643)
87. Emons G, Ortmann O, Schulz KD, Schally AV. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997; 8:355-362. (Pubitemid 28034420)
88. Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146:1-14. (Pubitemid 34126412)
89. Emons G, Muller V, Ortmann O, Schulz KD. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998; 65:199-206. (Pubitemid 28335607)
90. Grundker C, Volker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001; 142:2369-2380. (Pubitemid 32473092)
91. Grundker C, Volker P, Schulz KD, Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 2000; 78:194-202. (Pubitemid 30650353)
92. Grundker C, Fost C, Fister S, et al. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast Cancer Res 2010; 12:R49.